Xu Ma1, Hui Yuan2, Hai-Xia Luan2, Ya-Li Shi3, Xiao-Li Zeng2, Yan Wang2. 1. Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood vessel Diseases, Beijing 100029, China. Electronic address: mangobj@163.com. 2. Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood vessel Diseases, Beijing 100029, China. 3. Ward of Heart Failure, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Abstract
BACKGROUND: The aim of this study is to investigate the value of soluble suppression of tumorigenicity 2 (sST2) in Atrial fibrillation (AF) patients' risk prediction. METHODS: Healthy people (n = 60) and AF patients (n = 194) were consecutively enrolled into this project. RESULTS: In the health group, the mean age was 54 y (55% males). Serum median concentration of sST2 in healthy individuals was 17.04 ng/ml. In the AF patients group, the mean age was 61 years, and 64% were males. Median sST2 value was 21.69 ng/ml. According to subgroup analysis, median sST2 value of paroxysmal and persistent AF patients was 19.82 ng/ml and 24.15 ng/ml, respectively. Emergency AF patients showed much higher median sST2 concentration than AF outpatients (41.59 ng/ml vs. 20.53 ng/ml, p < 0.01). By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration. After healthy people and AF patients with HF excluded, whether emergency visit or not become a patent predictor of sST2 concentration (n = 172). CONCLUSION: sST2 is probably an objective biomarker that can predict AF patients' risk of emergency admission or HF. Elevated sST2 concentration may involve in the progression of AF.
BACKGROUND: The aim of this study is to investigate the value of soluble suppression of tumorigenicity 2 (sST2) in Atrial fibrillation (AF) patients' risk prediction. METHODS: Healthy people (n = 60) and AFpatients (n = 194) were consecutively enrolled into this project. RESULTS: In the health group, the mean age was 54 y (55% males). Serum median concentration of sST2 in healthy individuals was 17.04 ng/ml. In the AFpatients group, the mean age was 61 years, and 64% were males. Median sST2 value was 21.69 ng/ml. According to subgroup analysis, median sST2 value of paroxysmal and persistent AFpatients was 19.82 ng/ml and 24.15 ng/ml, respectively. Emergency AFpatients showed much higher median sST2 concentration than AF outpatients (41.59 ng/ml vs. 20.53 ng/ml, p < 0.01). By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration. After healthy people and AFpatients with HF excluded, whether emergency visit or not become a patent predictor of sST2 concentration (n = 172). CONCLUSION: sST2 is probably an objective biomarker that can predict AFpatients' risk of emergency admission or HF. Elevated sST2 concentration may involve in the progression of AF.
Authors: Ruth Saez-Maleta; Ana Merino-Merino; Simon Gundin-Menendez; Ricardo Salgado-Aranda; Daniel AlKassam-Martinez; Virginia Pascual-Tejerina; Javier Martin-Gonzalez; Javier Garcia-Fernandez; Jose-Angel Perez-Rivera Journal: Mol Biol Rep Date: 2021-01-23 Impact factor: 2.316
Authors: Elena Palà; Alejandro Bustamante; Josep Lluis Clúa-Espuny; Juan Acosta; Felipe González-Loyola; Sara Dos Santos; Domingo Ribas-Segui; Juan Ballesta-Ors; Anna Penalba; Marina Giralt; Iñigo Lechuga-Duran; Delicia Gentille-Lorente; Alonso Pedrote; Miguel Ángel Muñoz; Joan Montaner Journal: PLoS One Date: 2022-08-23 Impact factor: 3.752